With 0.84 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.84 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.1500 whereas the lowest price it dropped to was $1.8600. The 52-week range on LYEL shows that it touched its highest point at $4.54 and its lowest point at $1.32 during that stretch. It currently has a 1-year price target of $6.50. Beta for the stock currently stands at -0.88.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LYEL was up-trending over the past week, with a rise of 25.16%, but this was up by 25.16% over a month. Three-month performance dropped to -10.60% while six-month performance fell -32.87%. The stock lost -56.01% in the past year, while it has lost -44.09% so far this year. A look at the trailing 12-month EPS for LYEL yields -0.76 with Next year EPS estimates of -0.87. For the next quarter, that number is -0.23. This implies an EPS growth rate of -25.14% for this year and 6.26% for next year.
Float and Shares Shorts:
At present, 249.57 million LYEL shares are outstanding with a float of 122.88 million shares on hand for trading. On Oct 30, 2023, short shares totaled 19.2 million, which was 7.62% higher than short shares on Sep 28, 2023. In addition to Dr. Richard D. Klausner M.D. as the firm’s Founder & Executive Chairman, Dr. Lynn Seely M.D., Ph.D. serves as its President, CEO & Director.
Other institutions hold 8.74% of LYEL, in contrast to 19.09% held by mutual funds. Shares owned by individuals account for 18.06%. As the largest shareholder in LYEL with 6.65% of the stake, The Vanguard Group, Inc. holds 16,682,308 shares worth 16,682,308. A second-largest stockholder of LYEL, BlackRock Fund Advisors, holds 11,428,715 shares, controlling over 4.55% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in LYEL, holding 6,810,428 shares or 2.71% stake. With a 2.46% stake in LYEL, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 6,174,266 shares are owned by the mutual fund manager. The T Rowe Price Health Sciences Fund, which owns about 2.05% of LYEL stock, is the second-largest Mutual Fund holder. It holds 5,150,608 shares valued at 8.52 million. Vanguard Small Cap Index Fund holds 1.80% of the stake in LYEL, owning 4,515,679 shares worth 7.47 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LYEL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With LYEL analysts setting a high price target of $9.00 and a low target of $4.00, the average target price over the next 12 months is $6.50. Based on these targets, LYEL could surge 363.92% to reach the target high and rise by 106.19% to reach the target low. Reaching the average price target will result in a growth of 235.05% from current levels.
Summary of Insider Activity:
Insiders traded LYEL stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 0 while 58,020 shares were sold.